Progestogen treatment options for early endometrial cancer

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 117, Issue 7, 2010, Pages 879-884

  Cade, Tj ^a   Quinn, Ma ^a,b   Rome, Rm ^a,b   Neesham, D ^a  

^a ROYAL WOMEN'S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Endometrial cancer; Levonorgestrel releasing intrauterine system; Progestins; Progestogens

Indexed keywords

GESTAGEN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; PROGESTERONE;

ADULT; ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CASE STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; CURETTAGE; DISEASE FREE SURVIVAL; DRUG TREATMENT FAILURE; ENDOMETRIUM CANCER; FEMALE; FEMALE FERTILITY; HUMAN; HYSTERECTOMY; INTRAUTERINE CONTRACEPTIVE DEVICE; MEDICAL DECISION MAKING; MEDICAL SPECIALIST; PATIENT DECISION MAKING; PATIENT SELECTION; PREGNANCY; PREMENOPAUSE; PRIORITY JOURNAL; TREATMENT OUTCOME; UTERUS SURGERY;

EID: 77952252742     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/j.1471-0528.2010.02552.x     Document Type: Article

References (28)

1. Victorian Cancer Registry.
2. Rose PG. Endometrial cancer. N Engl J Med 1996 335 : 640 649.
3. Elit L, Hirte H. Current status and future innovations of hormonal agents, chemotherapy and investigational agents in endometrial cancer. Curr Opin Obstet Gynecol 2002 14 : 67 73.
4. Garrett A, Quinn MA. Hormonal therapies and gynaecological cancers. Best Pract Res Clin Obstet Gynaecol 2008 22 : 407 421.
5. Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer: a Gynecologic Oncology Group Study. Cancer 1987 60 : 2035 2041.
6. Zaino RJ. Pathologic indicators of prognosis in endometrial adenocarcinoma: selected aspects emphasizing the GOG experience. Gynecologic Oncology Group. Pathol Annu 1995 30 : 1 28.
7. Martin-Hirsch PL, Jarvis G, Kitchener H, et al. Progestagens for endometrial cancer. Cochrane Database Syst Rev 2000 2 : CD001040.
8. Podczaski E, Mortel R. Hormonal treatment of endometrial cancer: past, present and future. Best Pract Res Clin Obstet Gynaecol 2001 15 : 469 489.
9. Lai C, Huang H. The role of hormones for the treatment of endometrial hyperplasia and endometrial cancer. Curr Opin Obstet Gynecol 2006 18 : 29 34.
10. Kleine W, Maier T, Geyer H, et al. Estrogen and progesterone receptors in endometrial cancer and their prognostic relevance. Gynecol Oncol 1990 38 : 59 65.
11. Zaino RJ. FIGO staging of endometrial adenocarcinoma: a critical review and proposal. Int J Gynecol Pathol 2009 28 : 1 9.
12. Tavassoli F, Kraus FT. Endometrial lesions in uteri resected for atypical endometrial hyperplasia. Am J Clin Pathol 1978 70 : 770 779.
13. Kurman RJ, Norris HJ. Evaluation of criteria for distinguishing atypical endometrial hyperplasia from well-differentiated carcinoma. Cancer 1982 49 : 2547 2559.
14. Hendrickson MR, Ross JC, Kempson RL. Toward the development of morphologic criteria for well-differentiated adenocarcinoma of the endometrium. Am J Surg Pathol 1983 7 : 819 838.
15. Kendall BS, Ronnett BM, Isacson C, Cho KR, Hedrick L, Diener-West M, et al. Reproducibility of the diagnosis of endometrial hyperplasia, atypical hyperplasia, and well differentiated carcinoma. Am J Surg Pathol 1998 22 : 1012 1019.
16. Wang CB, Wang CJ, Huang HJ, et al. Fertility-preserving treatment in young patients with endometrial adenocarcinoma. Cancer 2002 94 : 2192 2198.
17. Gotlieb W, Beiner M, Shalmon B, et al. Outcome of fertility-sparing treatment with progestins in young patients with endometrial cancer. Obstet Gynecol 2003 102 : 718 725.
18. Park JC, Cho CH, Rhee JH. A successful live birth through in vitro fertilization program after conservative treatment of FIGO grade I endometrial cancer. J Korean Med Sci 2006 21 : 567 571.
19. Yamazawa K, Hirai M, Fujito A, et al. Fertility-preserving treatment with progestin, and pathological criteria to predict responses, in young women with endometrial cancer. Hum Reprod 2007 22 : 1953 1958.
20. Chiva L, Lapuente F, González-Cortijo L, et al. Sparing fertility in young patients with endometrial cancer. Gynecol Oncol 2008 111 : S101 4.
21. Ramirez PT, Frumovitz M, Bodurka DC, et al. Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review. Gynecol Oncol 2004 95 : 133 138.
22. Montz FJ, Bristow RE, Bovicelli A, et al. Intrauterine progesterone treatment of early endometrial cancer. Am J Obstet Gynecol 2002 186 : 651 657.
23. Giannopoulos T, Butler-Manuel S, Tailor A. Levonorgestrel-releasing intrauterine system (LNG-IUS) as a therapy for endometrial carcinoma. Gynecol Oncol 2004 95 : 762 764.
24. Dhar KK, NeedhiRajan T, Koslowski M, Woolas RP. Is levonorgestrel intrauterine system effective for treatment of early endometrial cancer? Report of four cases and review of the literature. Gynecol Oncol 2005 97 : 924 927.
25. Susumu N, Aoki D, Suzuki N, Nozawa S. [Hormonal therapy for endometrial adenocarcinoma]. Gan To Kagaku Ryoho 2001 28 : 934 945. Japanese.
26. Wang HY, Shen L, Sun Z. [Endometrial adenocarcinoma in women 40 years old or younger by treatment with progestins: report of 6 cases and review of the literatures]. Zhonghua Fu Chan Ke Za Zhi 2006 41 : 237 241. Chinese.
27. Eftekhar Z, Izadi-Mood N, Yarandi F, Shojaei H, Rwzaei Z, Mohagheghi S. Efficacy of megesterol acetate (megace) in the treatment of patients with early endometrial adenocarcinoma: our experiences with 21 patients. Int J Gynecol Cancer 2009 19 : 249 252.
28. Wheeler DT, Bristow RE, Kurman RJ. Histologic alterations in endometrial hyperplasia and well-differentiated carcinoma treated with progestins. Am J Surg Pathol 2007 31 : 988 998.